지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
The ultimate objective of dyslipidemia management is to prevent and treat atherosclerotic cardiovascular diseases. It is important to combine lifestyle modification together with medication. To determine whether to start drug therapy, comprehensive consideration should be given to both the risk status for atherosclerotic cardiovascular disease and low density lipoprotein cholesterol levels. Drug treatment can be initiated according to whether the patients have coronary artery disease, ischemic cerebral infarction, peripheral artery disease, atherosclerotic artery diseases (abdominal aortic aneurysm, carotid artery stenosis), or diabetes, as well as the number of atherosclerotic risk factors (smoking, hypertension, low high density lipoprotein cholesterol level, family history of premature coronary artery disease, and age). Statin is the first-choice drug for the treatment of hypercholesterolemia. The first goal for drug therapy is to lower the low density lipoprotein cholesterol and the secondary goal is to lower the non-high density lipoprotein cholesterol level. Secondary causes of dyslipidemia should be considered and corrected before starting any medication. These recommendations are based on the new treatment guideline 2015 of Korean Society of Lipidology and Atherosclereosis and Korean Medical Association.
목차
등록된 정보가 없습니다.
참고문헌 (29)
참고문헌 신청
Committee for Guidelines for Management of Dyslipidemia / 2015 / 2015 Korean guidelines for management of dyslipidemia / J Lipid Atheroscler 4:61~92
European Association for Cardiovascular Prevention & Rehabilitation / 2011 / ESC/EAS guidelines for the management of dyslipidae-mias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) / Eur Heart J 32:1769~1818
Stone NJ / 2014 / 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Associa-tion Task Force on Practice Guidelines / Circulation 129(25 Suppl 2):S1~S45
National Cholesterol Education Program (NCEP) Expert Panel on Detection / 2002 / Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report / Circulation 106:3143~3421
Cannon CP / 2015 / Ezetimibe added to statin therapy after acute coronary syndromes / N Engl J Med 372:2387~2397
European Association for Cardiovascular Prevention & Rehabilitation / 2011 / ESC/EAS guidelines for the management of dyslipidae-mias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) / Eur Heart J 32:1769~1818
Stone NJ / 2014 / 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Associa-tion Task Force on Practice Guidelines / Circulation 129(25 Suppl 2):S1~S45
National Cholesterol Education Program (NCEP) Expert Panel on Detection / 2002 / Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report / Circulation 106:3143~3421
Cannon CP / 2015 / Ezetimibe added to statin therapy after acute coronary syndromes / N Engl J Med 372:2387~2397
이 논문의 저자 정보
최근 본 자료
댓글(0)
0